Blinatumomab
Acute Leukemia Of Ambiguous Lineage
Explore 43 assets in Acute Leukemia Of Ambiguous Lineage →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07636564CT.gov Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | — | Not Yet Recruiting | — | — | — |
NCT06317662CT.gov Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Leukemia Of Ambiguous Lineage
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Blinatumomab (this asset) | SWOG Cancer Research Network | P2 | CCC · 51 |
| Cyclophosphamide | SWOG Cancer Research Network | P2 | BB |
| L-Ofloxacin | Children's Oncology Group | P3 | BB |
| Cytarabine | SWOG Cancer Research Network | P2 | B |
| Vincristine Sulfate | Children's Oncology Group | P2 | B |
| Fludarabine | Janssen Research & Development, LLC | P2 | B |
| Methotrexate | SWOG Cancer Research Network | P2 | B |
| Revumenib | SWOG Cancer Research Network | P2 | B |
| (+)-Vincristine | SWOG Cancer Research Network | P2 | B |
+42 more in the Acute Leukemia Of Ambiguous Lineage cohort
Other indications for Blinatumomab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Precursor B-Cell Acute Lymphoblastic Leukemia | — | P3 | BBB · 72 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BBB · 72 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Blinatumomab in Acute Leukemia Of Ambiguous Lineage. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/blinatumomab-acute-leukemia-of-ambiguous-lineage
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →